What is the latest MOLBIO stock price?
The latest stored price for MOLBIO is Rs 1,438.60 as of 2026-10-09.
gimli
MOLBIO stock AI analysis
MOLBIO Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
MOLBIO DIAGNOSTICS LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available MOLBIO price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹1,438.60
1W return
-4.92%
1M return
+14.37%
3M return
n/a
6M return
n/a
1Y return
n/a
Market cap
₹n/a
PE
n/a
PB
n/a
ROE
+14.64%
ROCE
+18.28%
RSI
59.22
Turnover
₹112.19 cr
Why it can matter in screens
- Momentum: MOLBIO is below 50DMA, below 200DMA; RSI is 59.22.
- Returns: 1D -2.74%, 1W -4.92%, 1M +14.37%, 3M n/a, 1Y n/a.
- Trend levels: 52W high ₹1,686.80, 52W low ₹926.35, off high -14.71%.
- Liquidity: latest turnover is ₹112.19 cr; volume vs 20D is +0.20%.
- Valuation/profitability: PE n/a, PB n/a, ROE +14.64%, ROCE +18.28%.
- Growth: 3Y sales CAGR +63.70%, 3Y profit CAGR n/a.
Quick Answers
Is MOLBIO above its 50DMA and 200DMA?
MOLBIO is below 50DMA, below 200DMA. The latest 50DMA is n/a and the latest 200DMA is n/a.
What are MOLBIO PE, ROE and ROCE?
MOLBIO has PE n/a, ROE +14.64%, and ROCE +18.28% in Gimli's latest available snapshot.
How has MOLBIO performed recently?
MOLBIO has returned +14.37% over 1 month, n/a over 3 months, and n/a over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
No recent data available.
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 1,414.96 cr | 326.17 cr | 166.59 cr | n/a |
| 2025-03-31 | 997.48 cr | 254.99 cr | 145.10 cr | n/a |
| 2024-03-31 | 819.73 cr | 184.34 cr | 101.95 cr | n/a |
| 2023-03-31 | 322.43 cr | 47.91 cr | -0.73 cr | n/a |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 2,148.42 cr | 355.53 cr | 450.08 cr | 1,308.78 cr |
| 2025-03-31 | 1,461.56 cr | 114.75 cr | 146.93 cr | 967.28 cr |
| 2024-03-31 | 1,221.06 cr | 12.68 cr | 183.62 cr | 828.84 cr |
| 2023-03-31 | 1,034.21 cr | 6.97 cr | 118.53 cr | 737.34 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 50.38 cr | 0.36 cr | n/a |
| 2025-03-31 | 287.10 cr | 232.44 cr | n/a |
| 2024-03-31 | 9.57 cr | -6.54 cr | n/a |
| 2023-03-31 | 64.13 cr | 49.63 cr | n/a |
Shareholding Trend
No recent data available.
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 422,282.96 cr | 34.857273 | +15.50% | +6.12% |
| DIVISLAB | DIVI S LABORATORIES LTD | 247,947.67 cr | 85.088426 | +18.37% | +52.32% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 157,610.64 cr | 72.265309 | +17.33% | +31.16% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 115,423.17 cr | 58.937484 | +21.03% | +4.32% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,446.65 cr | 25.058308 | +16.04% | +12.37% |
| LAURUSLABS | LAURUS LABS LIMITED | 109,947.20 cr | 100.670416 | +21.77% | +135.42% |
| CIPLA | CIPLA LTD | 105,094.85 cr | 31.162389 | +10.25% | -14.02% |
| DRREDDY | DR. REDDY S LABORATORIES | 99,661.60 cr | 30.096514 | +9.23% | -3.94% |
Try these prompts
- Analyze MOLBIO DIAGNOSTICS with valuation, momentum and industry peers
- Compare MOLBIO with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare MOLBIO with other Healthcare stocks
Data snapshot: 2026-10-09. Not investment advice.